default author photo

Byoung-Gie Kim

Sungkyunkwan University - Department of Obstetrics and Gynecology

SCHOLARLY PAPERS

2

DOWNLOADS

116

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Efficacy and Safety of Triplet Maintenance Therapy (Olaparib, Pembrolizumab, And Bevacizumab) in BRCA Non-Mutated Patients with Platinum-Sensitive Recurrent Ovarian Cancer: A Multi-Centre, Single-Arm Phase II Study (OPEB-01/APGOT-OV4/MK 3475-B32)

Number of pages: 28 Posted: 21 Oct 2022
Yonsei University - Department of Obstetrics and Gynecology, Sungkyunkwan University - Biomedical Statistics Center, Seoul National University - Department of Obstetrics and Gynecology, Sungkyunkwan University - Department of Obstetrics and Gynecology, Yonsei University - Department of Obstetrics and Gynecology, Seoul National University - Department of Obstetrics and Gynecology, Sungkyunkwan University - Samsung Medical Center, Chinese Academy of Medical Sciences - Center for Gynecologic CancerNational Cancer Center, Korea - Center for Gynecologic Cancer, National University Health System (NUHS) - National University Cancer Institute, National University Health System (NUHS) - National University Cancer Institute and Yonsei University - Department of Obstetrics and Gynecology
Downloads 77 (830,555)

Abstract:

Loading...

Ovarian Neoplasms, Platinum-resistant, BRCA wild type, PARP inhibitor, Immunotherapy

2.

Efficacy and Safety of Pembrolizumab With or Without Lenvatinib in Recurrent Uterine Carcinosarcoma: a Real-World Single-Center Study

Number of pages: 25 Posted: 01 Oct 2025
Sungkyunkwan University - Samsung Medical Center, Sungkyunkwan University - Samsung Medical Center, Sungkyunkwan University - Samsung Medical Center, Sungkyunkwan University School of Medicine, Sungkyunkwan University - Samsung Medical Center, Sungkyunkwan University - Samsung Medical Center, Sungkyunkwan University - Department of Obstetrics and Gynecology and Sungkyunkwan University - Samsung Medical Center
Downloads 39 (1,236,159)

Abstract:

Loading...

Uterine carcinosarcoma, Recurrent endometrial cancer, Immunotherapy, Pembrolizumab, Real-world data